Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia

Bone Marrow Transplantation volume 41, pages 425–437 (2008)Cite this article

Abstract

Transplantation from unrelated donors (URD) is increasingly being used as treatment for hematological malignancies, including acute myeloid leukemia (AML). This increase is the consequence of the availability of more than 11 million URD volunteers and the more efficient donor search process in the recent years. Median time to identify a suitable URD is now 2 months. More than 50% of Caucasian patients have an human leukocyte antigen (HLA)-allele donor match and a one-antigen or allele HLA-mismatched donor may also be acceptable. Complications of URD transplants are particularly frequent and severe, with long-term OS in the registries being 10–20% inferior to HLA-identical sibling transplantation. High resolution DNA techniques for donor and recipient HLA matching have contributed to the survival in experienced centres after unrelated donor SCT approaching that achieved with sibling donors. The introduction of reduced intensity conditioning (RIC) has extended URD transplants to elderly and/or debilitated patients with AML. With this approach, TRM decreases, although graft-versus-host disease-related morbidity and mortality remain a problem. Despite this complication, results after URD transplantation in this age group seem better than those achieved with chemotherapy and/or autologous transplantation. To confirm this possibility, prospective multicenter comparisons of URD transplants after RIC with other treatment options for elderly AML patients have recently been started.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Cornelissen JJ, Löwenberg B . Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005; 151–155.

    Google Scholar 

  2. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    CAS  PubMed  Google Scholar 

  3. Sierra J, Anasetti C . Hematopoietic transplantation from adult unrelated donors. Curr Opin Org Transplant 2003; 8: 99–108.

    Google Scholar 

  4. Anasetti C, Perkins J, Nieder ML, Field T . Are matched unrelated donor transplants justified for AML in CR1? Best Pract Res Clin Haematol 2006; 19: 321–328.

    PubMed  Google Scholar 

  5. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    CAS  PubMed  Google Scholar 

  6. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, for the Joint Accreditation Comité of the Internacional Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). Results of the EBMT activity survey on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 391: 71–87.

    Google Scholar 

  7. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.

    CAS  PubMed  Google Scholar 

  8. Harousseau JL, Pignon B, Wicz F, Polin V, Tellier Z, Hurteloup P et al. Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Hematol Cell Ther 1996; 38: 381–391.

    CAS  PubMed  Google Scholar 

  9. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874–1882.

    CAS  PubMed  Google Scholar 

  10. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

    PubMed  Google Scholar 

  11. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232–1240.

    CAS  PubMed  Google Scholar 

  12. Cassileth P, Harrington D, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.

    CAS  PubMed  Google Scholar 

  13. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  14. Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM et al. Treatment of primary acute myeloid leukaemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as postremission strategy. Haematologica 2004; 89: 791–800.

    PubMed  Google Scholar 

  15. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T et al. The Hellenic Cooperative Group. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721–1731.

    CAS  PubMed  Google Scholar 

  16. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom? Results of a HOVON/SAKK donor versus no donor analysis. Blood 2007; 109: 3658–3666.

    CAS  PubMed  Google Scholar 

  17. Yanada M, Matsuo K, Emi N, Naoe T . Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103: 1652–1658.

    PubMed  Google Scholar 

  18. Sierra J, Bjerke J, Hansen J, Martin P, Petersdorf E, Woolfrey A et al. Marrow transplants from unrelated donors as treatment for acute leukemia. Leuk Lymphoma 2000; 39: 495–507.

    CAS  PubMed  Google Scholar 

  19. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

    CAS  PubMed  Google Scholar 

  20. Appelbaum FR . Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. Best Pract Res Clin Haematol 2007; 20: 67–75.

    PubMed  Google Scholar 

  21. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 110: 409–417.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751.

    CAS  PubMed  Google Scholar 

  23. Small D . FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006; 1: 178–184.

    Google Scholar 

  24. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226–4235.

    CAS  PubMed  Google Scholar 

  25. Guo Z, Hood L, Malkki M, Petersdorf EW . Long-range multilocus haplotype phasing of the MHC. Proc Natl Acad Sci USA 2006; 103: 6964–6969.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515–3520.

    CAS  PubMed  Google Scholar 

  27. Petersdorf E, Anasetti C, Martin PJ, Woolfrey A, Smith A, Mickelson E et al. Genomics of unrelated-donor hematopoietic cell transplantation. Curr Opin Immunol 2001; 13: 582–589.

    CAS  PubMed  Google Scholar 

  28. Shaw BE, Madrigal JA, Potter M . Improving outcome of unrelated donor stem cell transplantation by molecular matching. Blood Rev 2001; 15: 167–174.

    CAS  PubMed  Google Scholar 

  29. Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB et al. Effect of class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukaemia: the US National Marrow Donor Program Experience. Blood 2001; 98: 2922–2929.

    CAS  PubMed  Google Scholar 

  30. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T et al. Major-histocompatibility complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794–1800.

    CAS  PubMed  Google Scholar 

  31. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA-class I and class II high resolution matching on outcomes of unrelated donor BMT. HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104: 1923–1930.

    CAS  PubMed  Google Scholar 

  32. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200–4206.

    CAS  PubMed  Google Scholar 

  33. Petersdorf E, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004; 104: 2976–2980.

    CAS  PubMed  Google Scholar 

  34. Wade JA, Hurley CK, Takemoto SK, Thompson J, Davies SM, Fuller TC et al. HLA-mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood 2007; 109: 4064–4070.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer D, Eapen M et al. Single or multiple HLA-A, B, C or DRB1 mismatches limit success of unrelated donor bone marrow transplantation. Blood (ASH Annual Meeting Abstracts) 2006; 108: 55a (abstract 172).

    Google Scholar 

  36. Ringden O, Labopin M, Gluckman E, Hows JM, Bradley BA, Kolb HJ et al. Donor search or autografting in patients with acute leukemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplant 1997; 19: 963–968.

    CAS  PubMed  Google Scholar 

  37. Lazarus HM, Perez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132: 755–769.

    PubMed  Google Scholar 

  38. Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2004; 10: 310–319.

    CAS  PubMed  Google Scholar 

  39. De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    CAS  PubMed  Google Scholar 

  40. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.

    CAS  PubMed  Google Scholar 

  41. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379–1387.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006; 12: 61–67.

    PubMed  Google Scholar 

  43. Dini G, Cancedda R, Giorgiani G, Porta F, Messina C, Uderzo C et al. Association Italiana Ematologia e Oncologia Pediatrica and Gruppo Italiano per il Trapianto Midollo Osseo. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO). Haematologica 2002; 87: 51–57.

    PubMed  Google Scholar 

  44. Balduzzi A, Gooley T, Anasetti C, Sanders J, Martin PJ, Petersdorf E et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247–3256.

    CAS  PubMed  Google Scholar 

  45. Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horowitz EM et al. Outcomes of transplantation with matched sibling and unrelated donor bone marrow in children with leukemia. Lancet 1997; 350: 767–771.

    CAS  PubMed  Google Scholar 

  46. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145–151.

    PubMed  Google Scholar 

  47. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962–2971.

    CAS  PubMed  Google Scholar 

  48. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Charlson M, Szatrowski TO, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

    CAS  PubMed  Google Scholar 

  50. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246–4254.

    PubMed  Google Scholar 

  51. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, Sept 14 [e-pub ahead of print].

  52. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S et al. Single nucleotide polymorphisms in the NOD/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007; 25: 4262–4269.

    CAS  PubMed  Google Scholar 

  53. Marks DI, Bird JM, Vettenranta K, Hunt L, Green A, Cornish JM et al. T-cell depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2000; 6: 646–653.

    CAS  PubMed  Google Scholar 

  54. Krauter J, Heil G, Hoelzer D, Ottmann O, Martin H, Lubbert M et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood 2005; 106: 54a (abstract).

    Google Scholar 

  55. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.

    CAS  PubMed  Google Scholar 

  56. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants from umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.

    CAS  PubMed  Google Scholar 

  57. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813–3820.

    CAS  PubMed  Google Scholar 

  58. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaille C, Wagner J . Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006; 38: 83–93.

    CAS  PubMed  Google Scholar 

  59. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    PubMed  Google Scholar 

  60. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698–4707.

    CAS  PubMed  Google Scholar 

  61. Rocha V, Aversa F, Labopin M, Sanz G, Ciceri F, Arcese W et al. Outcomes of unrelated cord blood and haploidentical stem cell transplantation in adults with acute leukemias. Blood 2005; 106: 92a (ASH Annual Meeting Abstracts: 301).

    Google Scholar 

  62. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H . Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006; 19: 825–838.

    PubMed  Google Scholar 

  63. Estey E . Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908–1915.

    PubMed  Google Scholar 

  64. Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254–2262.

    PubMed  Google Scholar 

  65. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–3059.

    CAS  PubMed  Google Scholar 

  66. Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089–1095.

    CAS  PubMed  Google Scholar 

  67. Bertz H, Potthoff K, Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480–1484.

    PubMed  Google Scholar 

  68. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    CAS  PubMed  Google Scholar 

  69. Claxton DF, Ehmann C, Rybka W . Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130: 256–264.

    CAS  PubMed  Google Scholar 

  70. Blaise DP, Michel BJ, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931–1938.

    CAS  PubMed  Google Scholar 

  71. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    CAS  PubMed  Google Scholar 

  72. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675–5687.

    PubMed  Google Scholar 

  73. Platzbecker U, Thiede C, Fussel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707–714.

    CAS  PubMed  Google Scholar 

  74. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453.

    CAS  PubMed  Google Scholar 

  75. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379–1387.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R ; et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395–1400.

    CAS  PubMed  Google Scholar 

  77. Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 749–757.

    CAS  PubMed  Google Scholar 

  78. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.

    CAS  PubMed  Google Scholar 

  79. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454–462.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395–1400.

    CAS  PubMed  Google Scholar 

  81. Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Slavin S et al. Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. Results of genoidentical hematopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond—the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006; 24: 3959–3966.

    PubMed  Google Scholar 

  82. Lazarus HM, Rowe JM . Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20: 1673–1682.

    CAS  PubMed  Google Scholar 

  83. Storb R . Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007; 20: 85–90.

    PubMed  Google Scholar 

  84. Blaise D, Vey N, Faucher C, Mohty M . Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92: 533–541.

    PubMed  Google Scholar 

  85. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alentuzumab (FBC) conditioning. Blood 2004; 104: 1616–1623.

    CAS  PubMed  Google Scholar 

  86. Van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728–5738.

    CAS  PubMed  Google Scholar 

  87. Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study. Br J Haematol 2005; 130: 604–613.

    CAS  PubMed  Google Scholar 

  88. Van BK, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728–5738.

    Google Scholar 

  89. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144–151.

    CAS  PubMed  Google Scholar 

  90. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    CAS  PubMed  Google Scholar 

  91. Lima de M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    Google Scholar 

  92. Martino R, Caballero MD, Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243–2245.

    CAS  PubMed  Google Scholar 

  93. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 1007; 110: 2235–2241.

    Google Scholar 

Download references

Acknowledgements

This paper was supported in part by Grants PI051162, PI052312, RD06/0020/0101 and EC07/90065 from the ‘Instituto de Salud Carlos III’, Spain.

Author information

Authors and Affiliations

  1. Clinical Hematology Division and Hematopoietic Transplant Program, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

    J Sierra, R Martino, B Sánchez, J L Piñana, D Valcárcel & S Brunet

Authors
  1. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J L Piñana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Valcárcel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Sierra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sierra, J., Martino, R., Sánchez, B. et al. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant 41, 425–437 (2008). https://doi.org/10.1038/sj.bmt.1705973

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705973

Keywords

This article is cited by

Search

Advanced search

Quick links